In short
Clinical trials investigating "Antipsychotics" are studying how well these treatments work and how safe they are in specific patient groups. The trial data here focuses on people with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had endocrine therapy. These studies measure outcomes such as progression-free survival.
Key points
- Clinical trials investigating "Antipsychotics" in the provided data are focused on a Phase 3 comparison study in breast cancer. The study includes patients with locally advanced or metastatic hormone receptor-positive, HER2-negative disease who have already received endocrine therapy. It compares a study treatment against treatment of physician’s choice. The main goal is to measure progression-free survival, which shows how long the cancer stays from getting worse. The trial is authorised and plans to include 867 patients.
Trial overview
The provided clinical trial data for Antipsychotics describes one interventional study in people with breast cancer. The study is called “Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received Endocrine Therapy.” It is authorised and is designed to compare a study treatment with treatment chosen by the doctor.
Who can join the study
The target group is patients with locally advanced or metastatic breast cancer. The cancer must be hormone receptor-positive (HR-positive) and HER2-negative. The trial also requires that patients have already received an endocrine-based regimen, which means a treatment based on hormones or hormone control.
What is being compared
This is a comparison study, not a simple single-treatment study. The brief summary says the goal is to compare the effect of SG relative to the treatment of physician’s choice on progression-free survival. The intervention list includes multiple possible drugs and routes, showing that the control arm may include several treatment options chosen by the doctor.
Trial phase and size
This study is a Phase 3 trial. Phase 3 studies are usually done in larger groups of patients to compare treatments and confirm how well they work. The planned enrollment is 867 patients, which means the study aims to include 867 people.
Main endpoint and how it is measured
The main endpoint is progression-free survival (PFS). PFS is the time from randomization until the first objective progressive disease or death from any cause, whichever happens first. The trial uses blinded independent central review (BICR) and RECIST v1.1 to assess whether the cancer has grown.
What this means for patients
For patients, this trial is mainly asking whether one treatment approach can keep the cancer from getting worse for longer than the doctor’s chosen treatment. The study is focused on a specific breast cancer group, so not every patient with cancer would fit the trial. Because it is a Phase 3 study, the results are meant to give stronger evidence about treatment benefit in this population.